Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe and Russia.
Mediocre balance sheet with moderate growth potential.
Share Price & News
How has Mercator Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRC's share price has been volatile over the past 3 months.
7 Day Return
PL Medical Equipment
1 Year Return
PL Medical Equipment
Return vs Industry: MRC underperformed the Polish Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: MRC underperformed the Polish Market which returned -4.3% over the past year.
Price Volatility Vs. Market
How volatile is Mercator Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs Mercator Medical (WSE:MRC) Using Too Much Debt?
2 months ago | Simply Wall StThose Who Purchased Mercator Medical (WSE:MRC) Shares Three Years Ago Have A 56% Loss To Show For It
3 months ago | Simply Wall StWhat Kind Of Shareholders Own Mercator Medical S.A. (WSE:MRC)?
Is Mercator Medical undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: MRC (PLN9.98) is trading above our estimate of fair value (PLN1.92)
Significantly Below Fair Value: MRC is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MRC is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: MRC is unprofitable, so we can't compare its PE Ratio to the Polish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MRC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MRC is good value based on its PB Ratio (0.8x) compared to the PL Medical Equipment industry average (1x).
How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: MRC is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MRC's is expected to become profitable in the next 3 years.
Revenue vs Market: MRC's revenue (0.2% per year) is forecast to grow slower than the Polish market (5.1% per year).
High Growth Revenue: MRC's revenue (0.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MRC's Return on Equity is forecast to be low in 3 years time (11%).
How has Mercator Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRC is currently unprofitable.
Growing Profit Margin: MRC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MRC is unprofitable, and losses have increased over the past 5 years at a rate of -22.6% per year.
Accelerating Growth: Unable to compare MRC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MRC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (4.4%).
Return on Equity
High ROE: MRC has a negative Return on Equity (-1.18%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
How is Mercator Medical's financial position?
Financial Position Analysis
Short Term Liabilities: MRC's short term assets (PLN177.8M) exceed its short term liabilities (PLN148.3M).
Long Term Liabilities: MRC's short term assets (PLN177.8M) exceed its long term liabilities (PLN96.9M).
Debt to Equity History and Analysis
Debt Level: MRC's debt to equity ratio (109.5%) is considered high.
Reducing Debt: MRC's debt to equity ratio has increased from 44.4% to 109.5% over the past 5 years.
Debt Coverage: MRC's debt is well covered by operating cash flow (28.4%).
Interest Coverage: MRC is unprofitable, therefore interest payments are not well covered by earnings.
Inventory Level: MRC has a high level of physical assets or inventory.
Debt Coverage by Assets: MRC's debt is covered by short term assets (assets are 1.2x debt).
What is Mercator Medical's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MRC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MRC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MRC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MRC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: MRC is not paying a notable dividend for the Polish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRC's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
What is the CEO of Mercator Medical's salary, the management and board of directors tenure and is there insider trading?
Average management tenure
Wieslaw Zyznowski (55yo)
Dr. Wieslaw Zyznowski has been the Chairman of Management Board at Mercator Medical Spólka Akcyjna since 2010. In the 90s Dr. Zyznowski co-founded the Mercator. From 1991 to 2001 he served as (apart from a ...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD0.00) is below average for companies of similar size in the Polish market ($USD171.75K).
Compensation vs Earnings: Wieslaw's compensation has increased whilst the company is unprofitable.
Management Age and Tenure
Experienced Management: MRC's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.
Board Age and Tenure
Experienced Board: MRC's board of directors are considered experienced (6.4 years average tenure).
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Witold Kruszewski (44yo)
Vice-President of the Management Board & Financial Director
- Tenure: 1yrs
- Compensation: zł360.00k
Wieslaw Zyznowski (55yo)
Chairman of Management Board
- Tenure: 10yrs
- Compensation: zł480.00k
Monika Zyznowska (33yo)
Member of Management Board
- Tenure: 2.4yrs
Member of the Management Board
- Tenure: 0.2yrs
Jaroslaw Karasinski (52yo)
Member of Supervisory Board
- Tenure: 5.6yrs
Urszula Zyznowska (48yo)
Chairwoman of Supervisory Board
- Tenure: 10yrs
Piotr Solorz (48yo)
Vice Chairman of Supervisory Board
Marian Slowiaczek (69yo)
Member of Supervisory Board
- Tenure: 6.4yrs
Gabriela Stolarczyk-Zadecka (50yo)
Member of the Supervisory Board
Mercator Medical S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Mercator Medical S.A.
- Ticker: MRC
- Exchange: WSE
- Founded: 1989
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: zł107.797m
- Shares outstanding: 10.59m
- Website: https://mercatormedical.eu
- Mercator Medical S.A.
- Ul. H. Modrzejewskiej 30
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MRC||WSE (Warsaw Stock Exchange)||Yes||Bearer Shares||PL||PLN||Jan 2014|
|0QJM||LSE (London Stock Exchange)||Yes||Bearer Shares||GB||PLN||Jan 2014|
Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe and Russia. The company offers surgical gloves for conducting invasive surgeries that require sterile conditions; sterile examination and protective gloves for medical, outpatient, and diagnostic examinations, as well as therapeutic activities and working with septic materials; household gloves for use in gardening, housework, and cosmetic procedures; and protective and heavy-duty gloves. It also provides dressing products, such as gauze, non-woven fabric, non-woven cotton, sterile adhesive, and plaster dressing products, as well as medical adhesive tapes, elastic tubular bandages, absorption pads, and dialysis kits; and medical protective clothing, including caps, masks, medical coats and gowns, shoe covers, oversleeves, coveralls, scrub suits, and patients shirts. In addition, the company offers surgical drapes comprising sheets; non-woven drapes; surgical packs; and additional sterile items, which supplement the drape packs for the surgical site. Further, it provides professional services to food processing industry and gastronomy, pharmacies, cosmetology, and cleaning companies, as well as to uniformed services. The company markets its products under the ambulance, comfort, dermagel, ideal, nitrylex, opero, safeLINE, santex, and vinylex brands. It primarily serves hospitals, clinics, outpatient departments, doctor’s offices, and dental and veterinary clinics through direct sales, as well as through partners, tenders, and wholesale and retail sales. Mercator Medical S.A. was founded in 1989 and is headquartered in Kraków, Poland.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/01/27 22:23|
|End of Day Share Price||2020/01/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.